Precision Optics Reports Fourth Quarter and Fiscal Year 2025 Financial Results
Rhea-AI Summary
Precision Optics (NASDAQ: POCI) reported Q4 and FY 2025 financial results, with record Q4 revenue of $6.2 million, up 48% year-over-year. FY 2025 revenue was $19.1 million, with production revenue growing 34% to $14.2 million. The company reported a net loss of $(5.8) million for FY 2025.
For FY 2026, POCI projects revenue exceeding $25 million (31% growth) and expects gross margins to improve to approximately 30% from 18% in FY 2025. The company anticipates Adjusted EBITDA of $0.5 million in FY 2026, compared to $(3.7) million in FY 2025.
Additionally, POCI appointed Joseph Traut as new Chief Operating Officer effective October 1, 2025, granting him inducement stock options for 60,000 shares.
Positive
- Record Q4 2025 revenue of $6.2 million, up 48% year-over-year
- Production revenue grew 34% to $14.2 million in FY 2025
- FY 2026 guidance projects 31% revenue growth to over $25 million
- Expected improvement in gross margins from 18% to 30% in FY 2026
- Projected positive Adjusted EBITDA of $0.5 million for FY 2026
- Secured multi-year agreements with top tier aerospace and surgical robotics companies
Negative
- Net loss increased to $(5.8) million in FY 2025 from $(3.0) million in FY 2024
- Gross margins declined to 17.8% in FY 2025 from 30.3% in FY 2024
- Adjusted EBITDA worsened to $(3.7) million from $(1.6) million year-over-year
- Production challenges and yield issues impacting financial performance
- Unanticipated tariff costs affecting margins
News Market Reaction
On the day this news was published, POCI declined NaN%, reflecting a moderate negative market reaction. Trading volume was exceptionally heavy at 7.0x the daily average, suggesting significant selling pressure.
Data tracked by StockTitan Argus on the day of publication.
Conference Call Scheduled for today, September 29, 2025, at 5:00pm ET
Company introduces fiscal year 2026 Revenue and Adjusted EBITDA guidance
Company appoints new Chief Operating Officer
GARDNER, Mass., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ: POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, announced operating results on an unaudited basis for its fourth quarter and fiscal year 2025 for the period ended June 30, 2025.
Q4 2025 Financial Highlights (3 Months Ended June 30, 2025):
- Revenue was
$6.2 million , a new quarterly record, compared to$4.7 million in the same quarter of the previous fiscal year and compared to$4.2 million in the most recent sequential quarter, representing growth of approximately48% . - Production revenue was
$5.1 million compared to$2.8 million in the same quarter of the previous fiscal year and compared to$3.3 million in the most recent sequential quarter, representing growth of approximately54% . - Engineering revenue was
$1.1 million compared to$1.9 million in the same quarter of the previous fiscal year and compared to$0.9 million in the most recent sequential quarter. - Gross margins were
13.0% compared to21.7% in the same quarter of the previous fiscal year and compared to10.0% in the most recent sequential quarter. - Net loss for the quarter was
$(1.4) million , compared to$(1.4) million in the same quarter of the previous fiscal year, and compared to$(2.1) million in the most recent sequential quarter. - Adjusted EBITDA was
$(0.9) million for the quarter compared to$(1.1) million in the same quarter of the previous fiscal year and compared to$(1.3) million in the most recent sequential quarter.
FY 2025 Financial Highlights (Year Ended June 30, 2025):
- Revenue was
$19.1 million compared to$19.1 million in the previous fiscal year. - Production revenue was
$14.2 million compared to$10.6 million in the previous fiscal year, representing growth of approximately34% . Engineering revenue was$4.9 million compared to$8.5 million in the previous fiscal year. - Gross margins were
17.8% compared to30.3% in the previous fiscal year. - Net loss was (
$5.8) million compared to$(3.0) million in the previous fiscal year. - Adjusted EBITDA was
$(3.7) million compared to$(1.6) million in the previous fiscal year.
FY 2026 Financial Guidance (Year Ended June 30, 2026):
- The Company projects for the fiscal year 2026 revenue to be in excess of
$25 million , which represents31% growth over the Company’s fiscal year 2025 revenue. - The Company expects fiscal year 2026 gross margin to be approximately
30% , an improvement compared to18% in fiscal 2025. - The Company projects fiscal year 2026 Adjusted EBITDA be approximately
$0.5 million compared to$(3.7) million in fiscal 2025.
“During the fourth quarter, we reported quarterly revenue of
“Margins were impacted by production yields, staffing and efficiency challenges along with unanticipated tariff costs. During the first quarter of Fiscal 2026 we renegotiated pricing agreements with one customer to account for some of the yield shortfalls, and we expect the impact of design revisions and related manufacturing improvements to be in place later this year. These improvements are expected to result in continued gross margin gains from quarter to quarter during Fiscal 2026. Finally, we are kicking off new product development engagements resulting from our expanded outreach that will increase utilization of our engineering resources. All told, our expectation is for gross margin improvement of more than ten percentage points in fiscal 2026 with further improvements in future years.”
Appointment of New Chief Operating Officer
The Company today announced the appointment of Joseph Traut as the Company's new Chief Operating Officer effective October 1, 2025. Mr. Traut will lead the operations team, including its production and engineering activities at its facilities in Massachusetts, Maine and Texas. Prior to joining Precision Optics, he held senior operations management roles with numerous medical device companies. In connection with Mr. Traut joining the Company, in addition to his salary and benefits, the Compensation Committee and Board of the Company approved the grant of an inducement stock option to be granted on his Start Date, to purchase 60,000 shares of the Company’s common stock. The Option was granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of the individual’s employment compensation and was granted as an inducement material to his acceptance of employment with the Company. Mr. Traut’s option has an exercise price equal to the closing price of the Company’s common stock as reported by the Nasdaq Capital Market on October 1, 2025. The options have a ten-year term and vest in three equal annual installments, subject to Mr. Traut’s continued service with the Company through the applicable vesting dates.
Forkey commented, “I am pleased to welcome Joe Traut as our new COO. Joe has specific expertise in building effective operations teams and transferring manufacturing operations both internationally and domestically with a history of improving business performance through operational excellence methodology and improved manufacturing efficiency. I look forward to his contributions as we continue to rapidly scale our operations.”
The following table summarizes the fourth quarter and fiscal year results for the periods ended June 30, 2025, and 2024:
| Three Months | Year | |||||||||||||
| Ended June 30 | Ended June 30 | |||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||
| Revenues | $ | 6,181,342 | $ | 4,716,225 | $ | 19,091,269 | $ | 19,104,350 | ||||||
| Gross Profit | 799,187 | 1,024,450 | 3,404,433 | 5,797,778 | ||||||||||
| Stock Compensation Expenses | 439,873 | 210,393 | 1,612,106 | 959,784 | ||||||||||
| Other | 1,715,356 | 2,170,409 | 7,343,618 | 7,562,326 | ||||||||||
| Total Operating Expenses | 2,155,229 | 2,380,802 | 8,955,724 | 8,522,110 | ||||||||||
| Operating Income (Loss) | (1,356,042 | ) | (1,356,352 | ) | (5,551,291 | ) | (2,724,332 | ) | ||||||
| Net Income (Loss) | (1,402,555 | ) | (1,411,106 | ) | (5,780,246 | ) | (2,951,377 | ) | ||||||
| Income (Loss) per Share | ||||||||||||||
| Basic & Fully Diluted | $ | (0.18 | ) | $ | (0.23 | ) | $ | (0.85 | ) | $ | (0.49 | ) | ||
| Weighted Average Common Shares Outstanding | ||||||||||||||
| Basic & Fully Diluted | 7,690,084 | 6,071,846 | 6,790,466 | 6,068,329 | ||||||||||
Conference Call Details
Date and Time: Monday, September 29, 2025, at 5:00 p.m. ET.
Call-in Information: Interested parties can access the conference call by dialing (844) 735-3662 or
(412) 317-5705.
Live Webcast Information: Interested parties can access the conference call via a live webcast, which is available at https://app.webinar.net/09EyQ6EXoDx.
Replay: A teleconference replay of the call will be available for seven days, at (877) 344-7529 or (412) 317-0088, replay access code 3770234. A webcast replay will be available at https://app.webinar.net/09EyQ6EXoDx.
About Precision Optics Corporation
Founded in 1982, Precision Optics is a vertically integrated optics company primarily focused on leveraging its proprietary micro-optics, 3D imaging and digital imaging technologies to the healthcare and defense/aerospace industries by providing services ranging from new product concept through mass manufacture. Utilizing its leading-edge in-house design, prototype, regulatory and fabrication capabilities as well as its Ross Optical division's high volume world-wide sourcing, inspecting and production resources, the Company is able to design and manufacture next-generation product solutions to the most challenging customer requirements. Within healthcare, Precision Optics enables next generation medical device companies around the world to meet the increasing demands of the surgical community who require more enhanced and smaller imaging systems for minimally invasive surgery as well as 3D endoscopy systems to support the rapid proliferation of surgical robotic systems. In addition to these next generation applications, Precision Optics has supplied top tier medical device companies a wide variety of optical products for decades, including complex endocouplers and specialized endoscopes. The Company is also leveraging its technical proficiency in micro-optics to enable leading edge defense/aerospace applications which require the highest quality standards and the optimization of size, weight and power. For more information, please visit www.poci.com.
Non-GAAP Financial Measures
Precision Optics has provided in this press release financial information that has not been prepared in accordance with accounting principles generally accepted in the Unites States of America (“non-GAAP”). The non-GAAP financial measure is Adjusted EBITDA (earnings before interest, taxes, depreciation and amortization). In addition to the aforementioned items, Adjusted EBITDA also excludes from Net Income (Loss) the effect of stock-based compensation.
This non-GAAP financial measure assists Precision Optics management in comparing its operating performance over time because certain items may obscure the underlying business trends and make comparisons of long-term performance difficult, as they are of a nature and/or size that occur with inconsistent frequency or relate to discrete acquisition or restructuring plans that are fundamentally different from the ongoing productivity of the Company. Precision Optics management also believes that presenting this measure allows investors to view its performance using the same measures that the Company uses in evaluating its financial and business performance and trends.
Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information calculated in accordance with GAAP. Investors are encouraged to review the reconciliation of non-GAAP measures to their most directly comparable GAAP financial measures. A reconciliation of the non-GAAP financial measure presented above to GAAP results has been provided in the financial tables included with this press release.
About Forward-Looking Statements
This press release contains forward-looking statements within the meaning of U.S. federal securities laws. Any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. In addition, any statements that refer to projections, forecasts, or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intends," "may," "might," "plan," "possible," "potential," "predict," "project," "should," "would" and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements in this press release include, without limitation, the Company’s projections for future revenue, gross margins and Adjusted EBITDA. The forward-looking statements contained in this press release are based on certain assumptions and analyses made by the management of the Company in light of their respective experience and perception of historical trends, current conditions, and expected future developments and their potential effects on the Company as well as other factors they believe are appropriate in the circumstances. There can be no assurance that future developments affecting the Company will be those anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond the control of the parties), or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements, including the demand for the Company's products, global supply chains and economic activity in general and other risks and uncertainties identified in the Company's filings with the SEC. Should one or more of these risks or uncertainties materialize or should any of the assumptions being made prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required under applicable securities laws.
Company Contact:
PRECISION OPTICS CORPORATION
22 East Broadway
Gardner, Massachusetts 01440-3338
Telephone: 978-630-1800
Investor Contact:
LYTHAM PARTNERS, LLC
Robert Blum
Telephone: 602-889-9700
poci@lythampartners.com
| PRECISION OPTICS CORPORATION, INC. Balance Sheets at June 30, 2025 and 2024 | ||||||||
| 2025 | 2024 | |||||||
| ASSETS | ||||||||
| Current Assets: | ||||||||
| Cash and cash equivalents | $ | 1,773,735 | $ | 405,278 | ||||
| Accounts receivable, net of allowance for credit losses of | 4,336,730 | 3,545,491 | ||||||
| Inventories, net | 3,562,112 | 2,868,100 | ||||||
| Prepaid expenses | 385,390 | 299,364 | ||||||
| Total current assets | 10,057,967 | 7,118,233 | ||||||
| Fixed Assets: | ||||||||
| Machinery and equipment | 3,385,958 | 3,341,194 | ||||||
| Leasehold improvements | 871,356 | 810,914 | ||||||
| Furniture and fixtures | 538,428 | 416,425 | ||||||
| 4,795,742 | 4,568,533 | |||||||
| Less—Accumulated depreciation and amortization | 4,261,950 | 4,074,960 | ||||||
| Net fixed assets | 533,792 | 493,573 | ||||||
| Operating lease right-of-use asset | 141,825 | 189,999 | ||||||
| Patents, net | 232,493 | 286,559 | ||||||
| Goodwill | 8,824,210 | 8,824,210 | ||||||
| Total other assets | 9,198,528 | 9,300,768 | ||||||
| TOTAL ASSETS | $ | 19,790,287 | $ | 16,912,574 | ||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
| Current Liabilities: | ||||||||
| Revolving line of credit | $ | – | $ | 1,000,000 | ||||
| Current portion of capital lease obligation | 27,368 | 41,113 | ||||||
| Current maturities of long-term debt | 577,898 | 276,928 | ||||||
| Accounts payable | 2,909,100 | 1,397,313 | ||||||
| Customer advances | 1,821,929 | 1,172,350 | ||||||
| Accrued compensation and other | 764,004 | 840,662 | ||||||
| Operating lease liability | 50,995 | 178,450 | ||||||
| Total current liabilities | 6,151,294 | 4,906,816 | ||||||
| Capital lease obligation, net of current portion | – | 27,369 | ||||||
| Long-term debt, net of current maturities | 1,289,205 | 1,899,052 | ||||||
| Operating lease liability, net of current portion | 90,954 | 11,549 | ||||||
| Total liabilities | 7,531,453 | 6,844,786 | ||||||
| Stockholders’ Equity: | ||||||||
| Common stock, | 77,147 | 60,739 | ||||||
| Additional paid-in capital | 69,152,317 | 61,197,433 | ||||||
| Accumulated deficit | (56,970,630 | ) | (51,190,384 | ) | ||||
| Total stockholders’ equity | 12,258,834 | 10,067,788 | ||||||
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | $ | 19,790,287 | $ | 16,912,574 | ||||
| PRECISION OPTICS CORPORATION, INC. Statements of Operations for the Years Ended June 30, 2025 and 2024 | ||||||||
| 2025 | 2024 | |||||||
| Revenues | $ | 19,091,269 | $ | 19,104,350 | ||||
| Cost of goods sold | 15,686,836 | 13,306,573 | ||||||
| Gross profit | 3,404,433 | 5,797,777 | ||||||
| Research and development expenses, net | 1,157,963 | 981,781 | ||||||
| Selling, general and administrative expenses | 7,797,761 | 7,540,329 | ||||||
| Total operating expenses | 8,955,724 | 8,522,110 | ||||||
| Operating loss | (5,551,291 | ) | (2.724,333 | ) | ||||
| Other expense | ||||||||
| Interest expense | (227,019 | ) | (225,108 | ) | ||||
| Loss before provision for income taxes | (5,778,310 | ) | (2,949,441 | ) | ||||
| Provision for income taxes | 1,936 | 1,936 | ||||||
| Net loss | $ | (5,780,246 | ) | $ | (2,951,377 | ) | ||
| Loss per share: | ||||||||
| Basic and fully diluted | $ | (0.85 | ) | $ | (0.49 | ) | ||
| Weighted average common shares outstanding: | ||||||||
| Basic and fully diluted | 6,790,466 | 6,068,329 | ||||||
| PRECISION OPTICS CORPORATION, INC. Statements of Stockholders’ Equity for the Years Ended June 30, 2025 and 2024 | ||||||||||||||||||||
| Number of Shares | Common Stock | Additional Paid-in Capital | Accumulated Deficit | Total Stockholders’ Equity | ||||||||||||||||
| Balance, June 30, 2023 | 6,066,518 | $ | 60,665 | $ | 60,224,934 | $ | (48,239,007 | ) | $ | 12,046,592 | ||||||||||
| Proceeds from exercise of stock option | 4,333 | 43 | 12,746 | – | 12,789 | |||||||||||||||
| Exercise of stock options net of 2,916 shares withheld | 3,088 | 31 | (31 | ) | – | – | ||||||||||||||
| Stock-based compensation | – | – | 959,784 | – | 959,784 | |||||||||||||||
| Net loss | – | – | – | (2,951,377 | ) | (2,951,377 | ) | |||||||||||||
| Balance, June 30, 2024 | 6,073,939 | $ | 60,739 | $ | 61,197,433 | $ | (51,190,384 | ) | $ | 10,067,788 | ||||||||||
| Issuance of common stock in a registered direct offering | 1,538,368 | 15,384 | 6,254,752 | – | 6,270,136 | |||||||||||||||
| Proceeds from exercise of stock option | 71,979 | 721 | 88,329 | – | 89,050 | |||||||||||||||
| Issuance of common stock for consulting services and employees | 30,415 | 303 | 151,395 | – | 151,698 | |||||||||||||||
| Stock-based compensation | – | – | 1,460,408 | – | 1,460,408 | |||||||||||||||
| Net loss | – | – | – | (5,780,246 | ) | (5,780,246 | ) | |||||||||||||
| Balance, June 30, 2025 | 7,714,701 | $ | 77,147 | $ | 69,152,317 | $ | (56,970,630 | ) | $ | 12,258,834 | ||||||||||
| PRECISION OPTICS CORPORATION, INC. Statements of Cash Flows For the Years Ended June 30, 2025 and 2024 | ||||||||
| 2025 | 2024 | |||||||
| Cash Flows from Operating Activities: | ||||||||
| Net loss | $ | (5,780,246 | ) | $ | (2,951,377 | ) | ||
| Adjustments to reconcile net loss to net cash (used in) provided by operating activities- | ||||||||
| Depreciation and amortization | 212,439 | 212,382 | ||||||
| Stock-based compensation expense | 1,460,408 | 959,784 | ||||||
| Non-cash legal expense | 34,881 | – | ||||||
| Non-cash interest expense | 11,563 | 17,504 | ||||||
| Non-cash operating lease expense | 124 | – | ||||||
| Changes in operating assets and liabilities: | ||||||||
| Accounts receivable, net | (791,239 | ) | 361,916 | |||||
| Inventories | (694,012 | ) | (91,884 | ) | ||||
| Prepaid expenses | (86,026 | ) | (49,683 | ) | ||||
| Accounts payable | 1,511,787 | (1,034,951 | ) | |||||
| Contract liabilities | 649,579 | (2,340 | ) | |||||
| Accrued compensation and other | (76,658 | ) | (104,363 | ) | ||||
| Net cash used in operating activities | (3,547,400 | ) | (2,683,012 | ) | ||||
| Cash Flows from Investing Activities: | ||||||||
| Reclassification/additional patent costs | (6,264 | ) | (21,448 | ) | ||||
| Purchases of property and equipment | (227,209 | ) | (272,435 | ) | ||||
| Net cash used in investing activities | (233,473 | ) | (293,883 | ) | ||||
| Cash Flows from Financing Activities: | ||||||||
| Payment of capital lease obligations | (41,114 | ) | (43,209 | ) | ||||
| Principal payments of long-term debt | (280,440 | ) | (513,259 | ) | ||||
| Payment of debt issuance costs | (40,000 | ) | – | |||||
| (Repayments)/Borrowings on line of credit | (1,000,000 | ) | 1,000,000 | |||||
| Gross proceeds from registered direct offerings of common stock | 6,270,136 | – | ||||||
| Stock issued for services | 151,698 | – | ||||||
| Gross proceeds from exercise of stock options | 89,050 | 12,789 | ||||||
| Net cash provided by financing activities | 5,149,330 | 456,321 | ||||||
| Net increase (decrease) in cash and cash equivalents | 1,368,457 | (2,520,574 | ) | |||||
| Cash and cash equivalents, beginning of year | 405,278 | 2,925,852 | ||||||
| Cash and cash equivalents, end of year | $ | 1,773,735 | $ | 405,278 | ||||
| Supplemental disclosure of cash flow information: | ||||||||
| Cash paid during the year for income taxes | $ | 1,936 | $ | 1,936 | ||||
| Cash paid during the year for interest | $ | 216,456 | $ | 207,604 | ||||
| Operating right-of-use assets obtained in exchange for operating lease liabilities | $ | 133,650 | $ | – | ||||
| PRECISION OPTICS CORPORATION, INC. | |||||||||||||||||||
| RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES | |||||||||||||||||||
| ADJUSTED EBITDA | |||||||||||||||||||
| Three Months Ended | Year Ended | ||||||||||||||||||
| June 30 | June 30 | ||||||||||||||||||
| 2025 | 2024 | 2025 | 2024 | ||||||||||||||||
| Net Income (loss) (GAAP) | $ | (1,402,558 | ) | $ | (1,411,106 | ) | $ | (5,780,246 | ) | $ | (2,951,376 | ) | |||||||
| Stock based compensation | 439,873 | 210,393 | 1,612,106 | 959,784 | |||||||||||||||
| Depreciation and amortization | 60,263 | 55,796 | 212,439 | 212,382 | |||||||||||||||
| State Income Taxes | 1,936 | 1,936 | 1,936 | 1,936 | |||||||||||||||
| Interest expense | 44,576 | 52,818 | 227,019 | 225,108 | |||||||||||||||
| Adjusted EBITDA (non-GAAP) | $ | (855,910 | ) | $ | (1,090,163 | ) | $ | (3,726,746 | ) | $ | (1,552,166 | ) | |||||||
FAQ
What were Precision Optics (POCI) Q4 2025 earnings results?
What is Precision Optics (POCI) revenue guidance for fiscal year 2026?
Who is the new COO of Precision Optics (POCI)?
What caused the decline in Precision Optics (POCI) gross margins for FY 2025?
What were Precision Optics (POCI) full year 2025 financial results?
